
CLAIMS

[Claim 1] Use of a benzimidazole compound in the manufacture of a pharmaceutical composition for the treatment of obesity, diabetes, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis wherein the benzimidazole compound of formula I is:

[Chem.6]



Formula I

or pharmaceutically acceptable salts, crystals, hydrates, or solvates thereof.

[Claim 2] Use, according to claim 1, wherein the pharmaceutical composition for the treatment of obesity, diabetes, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis comprises pharmaceutical acceptable excipients.

[Claim 3] Use, according to claim 1, wherein the pharmaceutical composition comprises from 0.01 to 5000 mg of the benzimidazole compound of formula I.

[Claim 4] Use, according to claim 1, wherein acceptable salts of benzimidazole compound of formula I are chosen from the inorganic addition salts hydrochloride, hydrobromide, sulfate, nitrate, phosphate; from the organic additions salts acetate, propionate, hexanoate, heptanoate, glycolate, piruvate, lactate, malonate, malate, maleate, fumarate, tartrate, citrate, succinate, mesylate, acistrate, besylate, tosylate, xinafoate, benzoate, p-toluenesulfonate, cinnamate, p-

chlorobenzenesulfonate, 2-naphtalenesulfonate, p-toluenesulphonate, camphorsulfonate, trimethylacetate, t-butylacetate, laurylsulphate, gluconate, glutarate, hydroxynaphthoate, salicylate, stearate, muconate, mandelate, 2-hydroxyethanesulfonate; and from the alkaline addition salts of metals sodium, potassium, lithium, calcium, magnesium, bismuth, bromide; and from or pharmaceutically acceptable salts with the organic bases primary, secondary or tertiary amines; and salts with the aminoacid arginine, lysine, histidine, caffeine, procaine, hydrobamine, choline, betaine, ethylenediamine, glycosamine, teobromine, purine, morpholine.